GLP1R and obesity due to melanocortin 4 receptor deficiency: This review highlights the effectiveness of GLP-1A, especially semaglutide, in reducing weight as well as BMI in the adolescent obese non-diabetic population while maintaining safety. GLP-1 agonists have great potential to improve the health and quality of life of people with obesity and can prevent obesity-associated complications.